Chedule of DA and ADE regimens utilised in routine clinical practice and reported in the literature. Having said that, our study is the very first RCT on pediatric AML from LICs and LMICs. The study also challenges the dogma of three-drug induction chemotherapy in pediatric AML. To conclude, no statistically considerable difference in EFS, OS, CR, or toxicity among ADE and DA regimens in pediatric sufferers with AML was observed in our study. Future RCTs are required to seek out the optimal quantity of induction chemotherapy drugs and cycles in pediatric AML. Data AVAILABILITYThe data that help the findings of this study are accessible on request from the corresponding author. The data are certainly not publicly out there as a consequence of privacy or ethical restrictions. 25. five. six. 7. for pediatric acute myeloid leukemia in successive clinical trials: Improving EFS for Pediatric AML. Cancer. 2017;123:3791. Arora RS, Arora B. Acute leukemia in kids: A evaluation of the current Indian data. South Asian J Cancer. 2021;05:1550. Kulkarni KP, Marwaha RK. Childhood Acute Myeloid Leukemia: An Indian Viewpoint. Pediatr Hematol Oncol. 2011;28:2578. Van Weelderen RE, Klein K, Natawidjaja MD, De Vries R, Kaspers GJ. Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic overview of your literature. Professional Rev Anticancer Ther. 2021;21:7650. Ganguly S, Kinsey S, Bakhshi S. Childhood cancer in India. Cancer Epidemiol. 2021;71:101679. Gupta VG, Arora B, Radhakrishnan V, Banavali S, Bakhshi S.3-Methylglutaconic acid manufacturer Remedy rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India.Lasalocid custom synthesis Br J Haematol. 2016;175:346. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results in the Healthcare Analysis Council AML15 Trial. J Clin Oncol. 2013;31:3360. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results on the Medical Research Council’s 10th AML trial (MRC AML10).PMID:23907521 Adult and Childhood Leukaemia Functioning Parties from the Health-related Research Council. Blood. 1997;89:2311. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, et al. Idarubicin improves blast cell clearance through induction therapy in kids with AML: final results of study AML-BFM 93. Leukemia. 2001;15:3484. O’Brien TA, Russell SJ, Vowels MR, Oswald CM, Tiedemann K, Shaw PJ, et al. Results of consecutive trials for young children newly diagnosed with acute myeloid leukemia in the Australian and New Zealand Children’s Cancer Study Group. Blood. 2002;100:27086. D ner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B hner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international professional panel. Blood. 2017;129:4247. Prevalent Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed 15 Apr 2022). Development reference 5-19 years – Application tools. who.int/tools/ growth-reference-data-for-5to19-years/application-tools (accessed 10 Apr2022). Radhakrishnan V, Thampy C, Ganesan P, Rajendranath R, Ganesan TS, Rajalekshmy KR, et al. Acute Myeloid Leukemia in Kids: Experience from Tertiary Cancer Centre in India. Indian J Hematol Blood Transfus. 2016;32:2571. Antimicrobial Resistance Collaborators. Global burden of bact.